Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2002-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Amifostine may improve blood counts in patients with
myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating
patients who have myelodysplastic syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center